Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation

This study has been completed.
Information provided by:
Shanghai Jiao Tong University School of Medicine Identifier:
First received: February 22, 2010
Last updated: December 29, 2010
Last verified: December 2009
This study is designed to investigate the possible beneficial effects of UDCA on liver graft recovery early after adult liver transplantation.

Condition Intervention
Liver Transplantation
Ischemia-reperfusion Injury
Drug: ursodeoxycholic acid
Drug: identical-appearing placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:
  • Serum liver tests [ Time Frame: within the first 4 weeks after liver transplantation ]
    Serum liver tests include serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin (TB)

Secondary Outcome Measures:
  • Postoperative complications [ Time Frame: within the first 4 weeks after liver transplantation ]
    Postoperative complications include rates of acute cellular rejection (ACR), drug-induced hepatotoxicity, vascular or biliary complications, recurrence of primary liver disease and death

Enrollment: 112
Study Start Date: May 2005
Study Completion Date: January 2009
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ursodeoxycholic acid Drug: ursodeoxycholic acid
13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
Placebo Comparator: identical-appearing placebo Drug: identical-appearing placebo
13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All liver transplant patients in our center between May 2005 and April 2008 were potentially eligible for enrollment

Exclusion Criteria:

  • Age less than 18 years
  • Treatment with UDCA within one month before operation
  • Inability to provide written informed consent prior to study entry
  • Non-liver organ(s) failure prior to entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01073202

China, Shanghai
Shanghai First People's Hospital
Shanghai, Shanghai, China, 200080
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Study Chair: Zhi-Hai Peng, MD Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  More Information

Publications: Identifier: NCT01073202     History of Changes
Other Study ID Numbers: SFPH05B41
Study First Received: February 22, 2010
Last Updated: December 29, 2010

Additional relevant MeSH terms:
Reperfusion Injury
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Ursodeoxycholic Acid
Cholagogues and Choleretics
Gastrointestinal Agents processed this record on April 28, 2017